These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7679779)

  • 1. [Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome].
    Boermeester MA; van Leeuwen PA; Schneider AJ; Houdijk AP; Ferwerda CC; Wesdorp RI
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):337-42. PubMed ID: 7679779
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antagonists in neonatal sepsis].
    Mancilla-Ramírez J; Ramírez-Herrera M; Portillo-Gómez L; Gaitán-Meza J; Dinarello CA
    Bol Med Hosp Infant Mex; 1993 Sep; 50(9):691-3. PubMed ID: 7690571
    [No Abstract]   [Full Text] [Related]  

  • 3. Alternative views on the effects of recombinant interleukin-1-receptor antagonist.
    Vance-Bryan K; Hoey LL; Joslin SM
    Am J Hosp Pharm; 1994 Nov; 51(21):2724-7. PubMed ID: 7710539
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of recombinant interleukin-1-receptor antagonist.
    Barriere SL; Pribble JP
    Am J Hosp Pharm; 1994 May; 51(9):1253, 1257. PubMed ID: 8042646
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis.
    Fisher CJ; Opal SM; Lowry SF; Sadoff JC; LaBrecque JF; Donovan HC; Lookabaugh JL; Lemke J; Pribble JP; Stromatt SC
    Circ Shock; 1994 Sep; 44(1):1-8. PubMed ID: 7704933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sepsis therapy trials. Continued disappointment or reason for hope?
    Abraham E; Raffin TA
    JAMA; 1994 Jun; 271(23):1876-8. PubMed ID: 8196148
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of soluble mediators in sepsis and renal failure.
    Camussi G; Ronco C; Montrucchio G; Piccoli G
    Kidney Int Suppl; 1998 May; 66():S38-42. PubMed ID: 9573571
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-inflammatory cytokine levels in patients with septic shock.
    Kasai T; Inada K; Takakuwa T; Yamada Y; Inoue Y; Shimamura T; Taniguchi S; Sato S; Wakabayashi G; Endo S
    Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):34-42. PubMed ID: 9434313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cytokine responses in sepsis.
    Lowry SF; Moldawer LL
    Ann N Y Acad Sci; 1993 Jun; 685():471-82. PubMed ID: 8363256
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunotherapy of sepsis and septic shock].
    Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sepsis therapy still shocking.
    Nat Biotechnol; 1997 Jul; 15(7):601. PubMed ID: 9219250
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant bactericidal/permeability-increasing protein inhibits endotoxin-induced high-mobility group box 1 protein gene expression in sepsis.
    Zhang LT; Yao YM; Lu JQ; Yan XJ; Yu Y; Sheng ZY
    Shock; 2008 Feb; 29(2):278-84. PubMed ID: 17693935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 and interleukin-1 receptor antagonist.
    Dinarello CA
    Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New therapeutic strategies in severe sepsis and septic shock].
    Oddo M; Schaller MD; Calandra T; Liaudet L
    Rev Med Suisse Romande; 2004 Jun; 124(6):329-32. PubMed ID: 15293439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW; White AJ
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interleukin-1 receptor antagonist and its delivery by gene transfer.
    Evans CH; Robbins PD
    Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptors 2 and 4, and acute phase cytokine gene expression in dexamethasone and growth hormone treated dairy calves.
    Eicher SD; McMunn KA; Hammon HM; Donkin SS
    Vet Immunol Immunopathol; 2004 Apr; 98(3-4):115-25. PubMed ID: 15010221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.
    Lamping N; Dettmer R; Schröder NW; Pfeil D; Hallatschek W; Burger R; Schumann RR
    J Clin Invest; 1998 May; 101(10):2065-71. PubMed ID: 9593762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
    Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
    BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenic role of LBP in gram-negative sepsis and septic shock.
    Heumann D; Lengacher S; Le Roy D; Jongeneel CV; Glauser MP
    Prog Clin Biol Res; 1998; 397():379-86. PubMed ID: 9575578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.